COSMOS Pharmaceutical Corporation
CSMYF · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | $1,011,390 | $964,989 | $827,697 | $755,414 |
| % Growth | 4.8% | 16.6% | 9.6% | – |
| Cost of Goods Sold | $798,109 | $776,683 | $658,979 | $603,966 |
| Gross Profit | $213,281 | $188,306 | $168,718 | $151,448 |
| % Margin | 21.1% | 19.5% | 20.4% | 20% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $116 | $128 | $127 |
| SG&A Expenses | $0 | $1,928 | $122,807 | $107,756 |
| Sales & Mktg Exp. | $0 | $1,812 | $1,648 | $1,632 |
| Other Operating Expenses | $172,877 | $154,877 | $2,960 | $3,066 |
| Operating Expenses | $172,877 | $156,805 | $138,589 | $121,651 |
| Operating Income | $40,404 | $31,501 | $30,128 | $29,796 |
| % Margin | 4% | 3.3% | 3.6% | 3.9% |
| Other Income/Exp. Net | $1,968 | $2,218 | $2,644 | $3,251 |
| Pre-Tax Income | $42,372 | $33,719 | $32,773 | $33,048 |
| Tax Expense | $11,393 | $9,265 | $8,975 | $9,892 |
| Net Income | $30,978 | $24,454 | $23,797 | $23,155 |
| % Margin | 3.1% | 2.5% | 2.9% | 3.1% |
| EPS | 390.86 | 308.61 | 600.95 | 584.74 |
| % Growth | 26.7% | -48.6% | 2.8% | – |
| EPS Diluted | 390.86 | 308.61 | 600.95 | 584.74 |
| Weighted Avg Shares Out | 79 | 79 | 40 | 40 |
| Weighted Avg Shares Out Dil | 79 | 79 | 40 | 40 |
| Supplemental Information | – | – | – | – |
| Interest Income | $48 | $44 | $47 | $52 |
| Interest Expense | $254 | $99 | $51 | $52 |
| Depreciation & Amortization | $22,229 | $19,924 | $17,368 | $15,110 |
| EBITDA | $64,855 | $53,742 | $50,192 | $48,210 |
| % Margin | 6.4% | 5.6% | 6.1% | 6.4% |